Neuracle Genetics
- Biotech or pharma, therapeutic R&D
Overview
Neuracle Genetics is a clinical-stage biotechnology company dedicated to transforming patient lives through innovative adeno-associated virus (AAV) gene therapies. Leveraging cutting-edge AAV technology, we address unmet medical needs in ophthalmology and neurology.
Lead program
Our lead candidate, NG101, is a best-in-class AAV gene therapy for wet age-related macular degeneration (wAMD). NG101 is currently in a Phase 1/2a clinical trial, evaluating safety and efficacy in patients with wAMD.
Pipeline
Neuracle Genetics is advancing a robust preclinical pipeline, including:
- NG201: A first-in-class AAV gene therapy for neuropathic pain and Alzheimer's disease.
- NG103: A first-in-class AAV gene therapy for dry age-related macular degeneration (dAMD).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}